Marvel Announces the Second of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide Following Cessation of Drug Treatment

Stock Information for Marvel Biosciences Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Marvel Biosciences Corp.

Marvel Biosciences Announces Grant of Deferred Share Units
Marvel Biosciences Announces Acceleration of Warrant Expiry Date
Marvel Biosciences Granted Chinese Patent for Lead Therapeutic Candidate MB-204
Marvel Biosciences Announces Grant of Deferred Share Units
Marvel Biosciences Announces Closing of Private Placement
Marvel Biosciences Announces Closing of Second Tranche of Private Placement
Marvel Biosciences to Give Oral Presentation at The Annual IRSF Rett Syndrome Scientific Meeting
Marvel Biosciences Selected to Present Alzheimer's Research at the 2025 Alzheimer's Association International Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.